SCHEMBL3021979

SCHEMBL3021979

O=S(=O)(c1c(F)c(Br)cc(F)c1Br)N1CCN(c2nc(-c3ccc(F)c(F)c3)cs2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.53
ALDH1A1 P00352 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
MAPK1 P28482 4/20 0.49
LMNA P02545 5/20 0.47
MAPT P10636 4/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
USP2 O75604 1/20 0.47
RECQL P46063 1/20 0.47
HSD17B10 Q99714 1/20 0.47
RAB9A P51151 4/20 0.42
NPC1 O15118 3/20 0.41
POLB P06746 1/20 0.40
AR P10275 3/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
GAA P10253 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3652494 0.94 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3010177 0.93 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3002611 0.93 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3006456 0.91 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3019023 0.91 AR (0.52) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3017661 0.90 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3011535 0.90 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3017454 0.89 MAPK1 (0.57) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL2998245 0.89 MAPT (0.51) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL3013233 0.89 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1L3MBTL1MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.